Heart Drug Launch
- All
- News
-
Novartis Gets US Regulator's Nod for Heart Drug
Drug firm Novartis has received approval from the US Food and Drug Administration (FDA) for its heart failure treatment tablets, LCZ696, and the company plans to launch the medicine in India.
-
Heart Drug Launch Could be 'Most Exciting Ever', Says Novartis
The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
-
Pfizer's weak drug pipeline fuels hunger for AstraZeneca
At the heart of Pfizer Inc's pursuit of British drugmaker AstraZeneca Plc is a shortage of attractive products in its own research pipeline, aggravated by a recent series of disappointing drug launches, according to some industry analysts and money managers.
-
Ranbaxy launches Daiichi’s heart drug in India
Ranbaxy Laboratories on Thursday launched a generic version of Prasugrel, used in treating heart diseases, from Daiichi Sankyo portfolio in India as part of strategy to launch drugs from the parent company's stable. The product, Prasita, is the second drug from Daiichi Sankyo portfolio which has been introduced in India to be sold through R...
-
Novartis Gets US Regulator's Nod for Heart Drug
Drug firm Novartis has received approval from the US Food and Drug Administration (FDA) for its heart failure treatment tablets, LCZ696, and the company plans to launch the medicine in India.
-
Heart Drug Launch Could be 'Most Exciting Ever', Says Novartis
The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
-
Pfizer's weak drug pipeline fuels hunger for AstraZeneca
At the heart of Pfizer Inc's pursuit of British drugmaker AstraZeneca Plc is a shortage of attractive products in its own research pipeline, aggravated by a recent series of disappointing drug launches, according to some industry analysts and money managers.
-
Ranbaxy launches Daiichi’s heart drug in India
Ranbaxy Laboratories on Thursday launched a generic version of Prasugrel, used in treating heart diseases, from Daiichi Sankyo portfolio in India as part of strategy to launch drugs from the parent company's stable. The product, Prasita, is the second drug from Daiichi Sankyo portfolio which has been introduced in India to be sold through R...
